EN IT

Publications List

updated 10.10.2017

110. Gallotta A, Giannarini G, Laurini L, Zani D, Garbeglio A, Guazzieri S, Plebani M, Fassina G, Zattoni F. Clinical validation of the iXip index in avoiding unnecessary prostate biopsy: results from a prospective multicenter study involving 426 patients. Cancer Treat Res Comm. 10:40-45. 2017. doi: 10.1016/j.ctarc.2017.01.002
109. Gil-Gómez A, Ampuero J, Gallego-Durán R, Fassina G, Ferrer MT, Liu C, Pontisso P, Romero-Gómez M. Utility of SCCA-IgM levels in the prediction of hepatocellular carcinoma in cirrhotic patients. EASL HCC Summit. Geneva, Switzerland. 2017.
108. Guarino M, Di Costanzo GG, Gallotta A, Tortora R, Paneghetti L, Auriemma F, Tuccillo C, Fassina G, Caporaso N, Morisco F. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. Scand J Clin Lab Invest. 77(6):448-453. 2017. doi: 10.1080/00365513.2017.1336569
107. Ricco G, Cavallone D, Pontisso P, Fassina G, Gallotta A, Colombatto P, Oliveri F, Romagnoli V, Coco B, Salvati A, Bonino F, Brunetto MR. In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy. Dig Liver Dis. 49S:e48. 2017. doi: 10.1016/j.dld.2017.01.099
106. Ricco G, Cavallone D, Pontisso P, Fassina G, Gallotta A, Colombatto P, Oliveri F, Romagnoli V, Coco B, Salvati A, Bonino F, Brunetto MR. In hepatitis C infected patients with cirrhosis squamous cell carcinoma antigen (SCCA)-IgM levels may contribute to identify the individual risk of hepatocellular carcinoma development after antiviral therapy. EASL International Liver Congress (ILC). Amsterdam, Holland. 2017.
105. Biasiolo A, Martini A, Gallotta A, Fassina G, Pontisso P. Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as biomarker in liver disease: biological aspects and clinical applications. Biom Liver Dis. 1-22. 2016. doi: 10.1007/978-94-007-7742-2_15-1
104. Biasiolo A, Trotta E, Fasolato S, Ruvoletto M, Martini A, Gallotta A, Fassina G, Angeli P, Gatta A, Pontisso P. Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. Dig Liver Dis. 48(2):197-202. 2016. doi: 10.1016/j.dld.2015.10.022
103. Damborský P, Koczula KM, Gallotta A, Katrlík J. Lectin-based lateral flow assay: proof-of-concept. Analyst. 141:6444-48. 2016. doi: 10.1039/C6AN01746K
102. Francavilla S, Ferretti S, Gnocchi C, Dipalo M, Aloe R, Gallotta A, Fassina G, Ziglioli C, Simeone U, Maestroni U. Clinical evaluation of immune complex predictive index (iXip) to avoid unnecessary negative biopsies for prostate cancer. 89° Congresso SIU. Venice, Italy. 2016.
101. Gil-Gómez A, Ampuero J, Gallego-Durán R, Fassina G, Pontisso P, Romero-Gomez M. SCCA-IgM helps to identify patients at risk of long-term hepatocellular carcinoma. Hepatology. 64(S1):656A. 2016. doi: 10.1002/hep.28799
100. Koczula KM, Gallotta A. Lateral flow assays. Essays Biochem. 60:111-20. 2016. doi: 10.1042/EBC20150012
99. Crescenzi M, Tessari A, Biasiolo A, Padoan A, Gallotta A, Fassina G, Panciatichi C, Rossetto O, Pontisso P, Basso D, Plebani M. Analytical Validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma. Anal Methods. 7:629-637. 2015. doi: 10.1039/C4AY02495H
98. Gallotta A, Mràzovà V, Bednàrovà A, Kruzlicovà D, Frecer V, Miertus S, Fattovich G, Biasiolo A, Martini A, Ieluzzi D, Guido M, Pontisso P, Fassina G. A novel algorithm based on serum SCCA-IgM determination combined with common clinical data improves prediction of histological NASH. Dig Liver Dis. 47S:e226. 2015. doi: 10.1016/j.dld.2015.07.025
97. Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients. J Viral Hepat. 22(10):800-808. 2015. doi: 10.1111/jvh.12394
96. Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen immunoglobulins M to monitor chronic hepatitis C. World J Hepatol. 7(29):2913-2919. 2015. doi: 10.4254/wjh.v7.i29.2913
95. Morisco F, Guarino M, Di Costanzo GG, Gallotta A, Fassina G, Tortora R, Tuccillo C, Granata R, Loperto I, Auriemma F, Caporaso N. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients. J Hepatol. 62:S450. 2015. doi: 10.1016/S0168-8278(15)30582-1
94. Tzouvadaki I, Parrozzani C, Gallotta A, De Micheli G, Carrara S. Memristive Biosensors for PSA-IgM Detection. BioNanoSci. 5:189-195. 2015. doi: 10.1007/s12668-015-0179-4
93. Biasiolo A, Trotta E, Fasolato S, Tono N, Ruvoletto M, Martini A, Terrin L, Fassina G, Angeli P, Gatta A, Pontisso P. P569 SCCA-IgM is predictive of hepatocellular carcinoma development in patients with hcv cirrhosis. A prospective study. J Hepatol. 60:S259. 2014. doi: 10.1016/S0168-8278(14)60731-5
92. Gallotta A, Fassina G. Optical Biochips for Biomarkers-IgM Complexes Codetermination in Hepatocellular Carcinoma. . In Sensors (pp. 85-88). Springer New York. 2014.
91. Guarino M, Di Costanzo G G, Gallotta A, Fassina G, Tortora R, Tuccillo C, Auriemma F, Caporaso N, Morisco F. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients. Dig Liver Dis. 46:e137. 2014. doi: 10.1016/j.dld.2014.08.020
90. Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. Genotype 3 and circulating SCCA-IgM are independently associated with histological features of NASH in HCV infected patients. Dig Liver Dis. 46:e26. 2014. doi: 10.1016/j.dld.2014.01.061
89. Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. P837 Genotype 3 and circulating SCCA-IgM are independently associated with histological features of nash in hcv infected patients. J Hepatol. 60:S350-S351. 2014. doi: 10.1016/S0168-8278(14)60998-3
88. Biasiolo A, Tono N, Zaninotto M, Merkel C, Fassina G, Plebani M, Gatta A, Pontisso P. Specificity of squamous cell carcinoma antigen (SCCA)-IgM detection in patients with HCV infection and rheumatoid factor seropositivity. J Med Virol. 85:1005-8. 2013. doi: 10.1002/jmv.23493
87. Gallotta A, Ziglioli F, Ferretti S, Maestroni U, Moretti M, Aloe R, Gnocchi C, Di Palo M, Fassina G. A novel algorithm for the prediction of prostate cancer in clinically suspected patients. Cancer Biomark. 13:227-34. 2013. doi: 10.3233/CBM-130357
86. Matteucci C, Sorrentino R, Bellis L, Ettorre GM, Svicher V, Santoro R, Vennarecci G, Biasiolo A, Pontisso P, Scacciatelli D, Beneduce L, Sarrecchia C, Casalino P, Bernardini S, Pierimarchi P, Garaci E, Puoti C, Rasi G. Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis. Hepatol. Res. Epub. 2013. doi: 10.1111/hepr.12239
85. Morisco F, Di Costanzo GG, Guarino M, Tortora R, Loperto I, Auriemma F, Ferraiuoli C, Tuccillo C, Beneduce L, Caporaso N . SCCA-IgM: a biomarker to monitor the outcome of therapy with sorafenib in advanced HCC. Dig Liver Dis. 45:S217-18. 2013. doi: 10.1016/S1590-8658(13)60622-2
84. Morisco F, Di Costanzo GG, Guarino M, Tortora R, Loperto I, Clery E, Auriemma F, Tuccillo C, Beneduce L, Caporaso N. Circulating SCCA-IgM complex is able to monitor the success of loco-regional therapy in HCC patients. Dig Liver Dis. 45:S218. 2013. doi: 10.1016/S1590-8658(13)60623-4
83. Morisco F, Di Costanzo GG, Guarino M, Tortora R, Loperto I, Tuccillo C, Ferraiuoli C, Beneduce L, Auriemma F, Caporaso N. Su1001 Circulating Scca-IgM Complex Is an Useful Biomarker to Monitor HCC Therapy. Gastroenterology. 144:S-991. 2013. doi: 10.1016/S0016-5085(13)63676-8
82. Biasiolo A, Tono N, Ruvoletto M, Quarta S, Turato C, Villano G, Beneduce L, Fassina G, Merkel C, Gatta A, Pontisso P. IgM-linked SerpinB3 and SerpinB4 in sera of patients with chronic liver disease. PLoS ONE. 7:e40658. 2012. doi: 10.1371/journal.pone.0040658
81. Buccione D, Fatti G, Gallotta A, Loggi E, Di Donato R, Testa L, Saitta C, Santi V, Di Micoli A, Erroi V, Fazio V, Picciotto A, Biasiolo A, Degos F, Pontisso P, Raimondo G, Trevisani F. Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis. OJGas. 2:56-61. 2012. doi: 10.4236/ojgas.2012.22012
80. Gallotta A, Orzes E, Fassina G. Biomarkers Quantification with Antibody Arrays in Cancer Early Detection. Clin Lab Med. 32:33-45. 2012. doi: 10.1016/j.cll.2011.11.001
79. Kongkamnerd J, Cappelletti L, Prandi A, Seneci P, Rungrotmongkol T, Jongaroonngamsang N, Frecer V, Milani A, Cattoli G, Terregino C, Capua I, Beneduce L, Gallotta A, Pengo P, Fassina G, Miertus S, De-Eknamkul W. Synthesis and In vitro Study of Novel Neuraminidase Inhibitors Against Avian Influenza Virus. Bioorg Med Chem. 2152-57. 2012. doi: 10.1016/j.bmc.2012.01.026
78. Kongkamnerd J, Milani A, Cattoli G, Terregino C, Capua I, Beneduce L, Gallotta A, Pengo P, Fassina G, Miertus S, De-Eknamkul W. A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system. J Enzyme Inhib Med Chem. 27:5-11. 2012.
77. Morisco F, Guarino M, Tortora R, Donnarumma L, Loperto I, Camera S, Mariniello A, Tuccillo C, Beneduce L, Di Costanzo GG, Caporaso N . Serum Levels of SCCA-IgM are related to the efficacy of HCC treatments. Dig Liver Dis. 44:S135. 2012. doi: 10.1016/S1590-8658(12)60373-9
76. Biasiolo A, Tono N, Briarava M, Beneduce L, Fassina G, Farinati F, Giacomin A, Matteucci C, Sorrentino R, Nitti D, Gatta A , Pontisso P. Improved diagnostic accuracy for HCC using a combination of IgM-linked biomarkers. Dig Liver Dis. 43:S91. 2011. doi: 10.1016/S1590-8658(11)60081-9
75. Buccione D, Fatti G, Gallotta A, Loggi E, Di Donato R, Testa L, Saitta C, Santi V, Di Micoli A, Fazio V, Picciotto A, Biasiolo A, Pontisso P, Raimondo G, Trevisani F. Serum SCCA-IgM as a predictor of hepatocellular carcinoma (HCC) in patients with liver cirrhosis. Dig Liver Dis. 43:S95. 2011. doi: 10.1016/S1590-8658(11)60094-7
74. Dinon F, Salvalaglio M, Gallotta A, Beneduce L, Pengo P, Cavallotti C, Fassina G. Structural refinement of protein A mimetic peptide. J Mol Recognit. 24:1087-94. 2011.
73. Fassina G. Le nanotecnologie nella diagnosi e nella terapia. ICF. 2:34-7. 2011.
72. Gomiero C, Pengo P, Gallotta A, Biasiolo A, Tono N, Gatta A, Pontisso P, Matteucci C, Fassina G, Beneduce L. Improved detection of HCC by co-determination of IgM anti-AFP antibodies and AFP-IgM immune complexes. J Hepatol. 54:S382. 2011.
71. Kongkamnerd J, Milani A, Cattoli G, Terregino C, Capua I, Beneduce L, Gallotta A, Pengo P, Fassina G, Monthakantirat O, Umehara K, De-Eknamkul W, Miertus S. The quenching effect of flavonoids on 4-methylumbelliferone, a potential pitfall in fluorimetric neuraminidase inhibition assays. J Biomol Screen. 16:755-764. 2011.
70. Turato C, Biasiolo A, Pengo P, Frecer V, Quarta S, Fasolato S, Ruvoletto M, Beneduce L, Zuin J, Fassina G, Gatta A, Pontisso P. Increased antiprotease activity of the SERPINB3 polymorphic variant SCCA-PD. Exp Biol Med. 236:281-90. 2011.
69. Pengo P, Veggiani G, Rattanemanee K, Gallotta A, Beneduce L, Fassina G. Solid Phase Synthesis of Protein Conjugates. J Mol Recognit. 23:551-8. 2010.
68. Quarta S, Vidalino L, Turato C, Ruvoletto MG, Calabrese F, Valente M, Cannito S, Fassina G, Parola M, Gatta A, Pontisso P. SERPINB3 induces epithelial-mesenchymal transition. J Pathol. 221:343-56. 2010.
67. Turato C, Calabrese F, Biasiolo A, Quarta S, Ruvoletto MG, Tono N, Paccagnella D, Fassina G, Merkel C, Harrison TJ, Gatta A, Pontisso P. SERPINB3 modulates TGF-beta expression in chronic liver disease. Lab Invest. 90:1016-23. 2010.
66. Veggiani G, Zuin J, Beneduce L, Pengo P, Fassina G. Combinatorial semisynthesis of biomarker-IgM complexes. J Biomol Screen. 15:1274-80. 2010.
65. Verna M, Pengo P, Gallotta A, Zani D, Costa S, Leon A, Gion M, Fassina G, Beneduce L. Improved detection of low grade prostate cancer by PSA-IgM assessment. Anticancer Res. 30:1486-7. 2010.
64. Villano G, Quarta S, Ruvoletto MG, Turato C, Vidalino L, Biasiolo A, Tono N, Lunardi F, Calabrese F, Dall'olmo L, Dedja A, Fassina G, Gatta A, Pontisso P. Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. Int J Mol Med. 25:137-43. 2010. doi: 10.3892/ijmm_00000323
63. Zani D, Costa S, Beneduce L, Fassina G, Simeoni C, Cosciani Cunico S. Immunità e cancro: ruolo degli immunocomplessi PSA-IgM nel cancro della prostata. Urologia. 77:1-3. 2010.
62. Zani D, Costa S, Pettenò A, Simeone C, Cosciani Cunico S, Leon AE, Gion M, Fassina G, Beneduce L. Combined role of serum assays of PSA-IgM and PSA for the diagnosis of prostate cancer. Anticancer Res. 30:1496-7. 2010.
61. Zuin J, Veggiani G, Pengo P, Gallotta A, Biasiolo A, Tono N, Gatta A, Pontisso P, Toth R, Cerin D, Frecer V, Meo S, Gion M, Fassina G, Beneduce L. Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis. Clin Chem Lab Med. 48:217-23. 2010. doi: 10.1515/CCLM.2010.044
60. Biasiolo A, Tono N, Beneduce L, Zuin J, Fassina G, Meo S, Paccagnella L, Mazzucco M, Farinati F, Giacomin A, Vanin V, Aldino M, Miola E, Donà S, Matteucci C, Sorrentino R, Rasi G, Gatta A, Pontisso P. Osteopontin-IgM as a marker for the diagnosis of hepatocellular carcinoma. Int J Biol Markers. 24:206. 2009.
59. Biasiolo A, Tono N, Franzosi L, Beneduce L, Zuin J, Fassina G, Meo S, Paccagnella D, Mazzucco M, Farinati F, Giacomin A, Vanin V, Aldinio M, Miola E, Donà S, Gatta A, Pontisso P. Osteopontin-IgM in the diagnosis of HCC. Dig Liver Dis. 41:A4-A5. 2009. doi: 10.1016/j.dld.2009.02.017
58. Biasiolo A, Tono N, Quarta S, Beneduce L, Gatta A, Fassina G, Pontisso P. SCCA1-IgM and SCCA2-IgM compared with total SCCA-IgM for diagnosis of hepatocellular carcinoma. Int J Biol Markers. 24:205. 2009.
57. Bucca E, Beneduce L, Leon A, Fabricio A, Michilin S, Meo S, Vitale M, Steffan A, Durante C, Bellucco C, Rizzo A, Berlanda G, Perasole A, Zampieri F, Zuin J, Veggiani G, Fassina G, Gion M. The usefulness of the combination of free CA 15.3 and CA 15.3-IgM complexes for breast cancer diagnosis. Int J Biol Markers. 24:193. 2009.
56. Carrara S, Bhalla V, Stagni C, Benini C, Ferretti A, Valle F, Gallotta A, Riccio B, Samorì B. Label-free cancer markers detection by capacitance biochip. Sens Actuators B Chem. 136:163-172. 2009. doi: 10.1016/j.snb.2008.09.050
55. Gallotta A, Pengo P, Beneduce L, Fassina G. Combinatorial approaches in cancer early detection. Drug Design and Discovery for Developing Countries (Eds. Megnassan E, Owono Owono L, Miertus S) ICS-UNIDO. 206-18. 2009.
54. Gallotta A, Zuin J, Veggiani G, Pengo P, Biasiolo A, Tono N, Gatta A, Pontisso P, Fassina G, Beneduce L. Combining SCCA-IgM and AFP-IgM levels increases accuracy of hepatocellular carcinoma detection. Dig Liver Dis. 41:A15. 2009. doi: 10.1016/j.dld.2009.02.038
53. Gallotta A, Zuin J, Veggiani G, Pengo P, Leon A, Gion M, Biasiolo A, Tono N, Gatta A, Pontisso P, Fassina G, Beneduce L. Combination of biomarkers-IgM by logistic regression improves diagnostic accuracy in hepatocellular carcinoma. Int J Biol Markers. 24:208. 2009.
52. Matteucci C, Sorrentino R, Ettorre G, Bellis L, Antenucci A, Beneduce L, Santoro R, Vennarecci G, Zuin J, Biasiolo A, Pontisso P, Pierimarchi P, Puoti C, Rasi G. Circulating survivin-IgM is a novel candidate biomarker of cirrhosis and increases with child score in patients affected by liver disease. Int J Biol Markers. 24:210. 2009.
51. Matteucci C, Sorrentino R, Ettorre G, Bellis L, Antenucci A, Beneduce L, Santoro R, Vennarecci G, Zuin J, Pierimarchi P, Puoti C, Rasi G. Survivin-IgM immuno complex: a novel candidate biomarker of cirrhosis to monitor patients progression towards hepatocellular carcinoma. Dig Liver Dis. 41:A13. 2009. doi: 10.1016/j.dld.2009.02.035
50. Moiani D, Salvalaglio M, Cavallotti C, Bujacz A, Redzynia I, Bujacz G, Dinon F, Pengo P, Fassina G. Structural characterization of a Protein A mimetic peptide dendrimer bound to human IgG. J Phys Chem B. 113:16268-75. 2009.
49. Quarta S, Vidalino L, Turato C, Ruvoletto M, Calabrese F, Fassina G, Gatta A, Pontisso P. SERPINB3 induces epithelial mesenchymal transition. Dig Liver Dis. 41:A1-A2. 2009. doi: 10.1016/j.dld.2009.02.012
48. Turato C, Calabrese F, Biasiolo A, Quarta S, Ruvoletto M, Tono N, Franzosi L, Paccagnella D, Fassina G, Gatta A, Pontisso P. SERPINB3 and TGF-beta1 in chronic liver disease. Dig Liver Dis. 41:A13-A14. 2009. doi: 10.1016/j.dld.2008.12.030
47. Turato C, Calabrese F, Biasiolo A, Quarta S, Ruvoletto M, Tono N, Franzosi L, Paccagnella L, Fassina G, Gatta A. SERPINB3 and TGF-beta1 correlation in chronic liver disease. J Hepatol. 50:S117. 2009. doi: 10.1016/S0168-8278(09)60302-0
46. Turato C, Ruvoletto MG, Biasiolo A, Quarta S, Tono N, Bernardinello E, Beneduce L, Fassina G, Cavalletto L, Chemello L, Merkel C, Gatta A, Pontisso P. Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease. Dig Liver Dis. 41:212-6. 2009. doi: 10.1016/j.dld.2008.06.001
45. Zani D, Costa S, Gatti L, Pesenti N, Pettenò A, Zambolin T, Simeone C, Cunico S, Leon A, Zuin J, Pengo P, Fassina G, Beneduce L. The association of PSA-IgM and total PSA improves the diagnosis of prostate cancer. Int J Biol Markers. 24:212. 2009.
44. Zuin J, Veggiani G, Pengo P, Gallotta A, Biasiolo A, Tono N, Franzosi L, Pontisso P, Fassina G, Beneduce L. SCCA-IgM usefulness to monitor patients with cirrhosis is not affected by interfering IgM's. Dig Liver Dis. 41:A11. 2009. doi: 10.1016/j.dld.2009.02.031
43. Zuin J, Veggiani G, Pengo P, Gallotta A, Biasiolo A, Tono N, Gatta A, Pontisso P, Toth R, Cerin D, Frecer V, Meo S, Gion M, Fassina G, Beneduce L. Evaluation of the analytical specificity of SCCA-IgM assay for monitoring patients with cirrhosis. Int J Biol Markers. 24(3):209. 2009.
42. Beneduce L, Pesce G, Gallotta A, Zampieri F, Biasiolo A, Tono N, Boscato N, Gatta A, Pontisso P, Fassina G. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma. Eur J Clin Invest. 38:571-7. 2008. doi: 10.1111/j.1365-2362.2008.01985.x
41. Beneduce L, Pesce G, Gallotta A, Zampieri F, Biasolo A, Tono N, Pontisso P, Fassina G. Hepatocellular carcinoma induces specific IgM-biomarkers immune complexes. Dig Liver Dis. 40:A32. 2008. doi: 10.1016/j.dld.2007.12.083
40. Biasiolo A, Chemello L, Quarta S, Cavalletto L, Bortolotti F, Caberlotto C, Beneduce L, Bernardinello E, Tono N, Fassina G, Gatta A, Pontisso P. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. J Viral Hepat. 15:246-9. 2008. doi: 10.1111/j.1365-2893.2007.00935.x
39. Biasiolo A, Tono N, Beneduce L, Zuin J, Gatta A, Fassina G, Pontisso P. Vascular endothelial growth factor (VEGF)-IgM complex for the diagnosis of hepatocellular carcinoma. Gut. 57:A145. 2008.
38. Biasiolo A, Tono N, Quarta S, Beneduce L, Gatta A, Fassina G, Pontisso P. Squamous cell carcinoma antigen (SCCA)-IgM complex: SCCA1-IgM and SCCA-IgM compared to total SCCA-IgM for diagnosis of hepatocellular carcinoma. Gut. 57:A147. 2008.
37. Bucca E, Beneduce L, Leon A, Fabricio A, Michilin S, Steffan A, Durante C, Bellucco C, Rizzo A, Berlanda G, Perasole A, Zampieri F, Zuin J, Fassina G, Gion M. The combination of free CA15.3 and CA15.3-IgM complexes enhances discrimination between healthy subjects and breast cancer patients. Ann Oncol. 19:ix95. 2008. doi: 10.1093/annonc/mdn617
36. Gallotta A, Pengo P, Beneduce L, Fassina G. Factors affecting biochip design for cancer early detection. NanotechIT. 10:33-7. 2008.
35. Vidalino L, Quarta S, Baesso I, Fassina G, Gatta A, Pontisso P, Doria A. Squamous cell carcinoma antigen (SCCA) expression and CD27+ memory B lymphocytes in patients with chronic hepatitis C and systemic lupus erythematosus (SLE). Clin Exp Rheumatol. 26:S83. 2008.
34. Beneduce L, Prayer-Galetti T, Giustinian AMG, Gallotta A, Betto G, Pagano F, Fassina G. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients. Cancer Detect Prev. 31:402-7. 2007. doi: 10.1016/j.cdp.2007.10.005
33. Vidalino L, Quarta S, Baesso I, Bernardinello E, Ruvoletto M, Frezzato F, Trentin L, Fassina G, Cavalletto L, Chemello L, Gatta A, Pontisso P. Squamosus cell carcinoma antigen (SCCA) expression and CD27+ memory B lymphocytes in patients with chronic hepatitis C. J Hepatol. 46:S179. 2007. doi: 10.1016/S0168-8278(07)62069-8
32. Beneduce L, Gallotta A, Marino M, Fassina G. Des-gamma-carboxy prothrombin-IgM immune complexs as novel biomarker for hepatocellular carcinoma. J Hepatol. 44:S96. 2006. doi: 10.1016/S0168-8278(06)80241-2
31. Beneduce L, Gallotta A, Marino M, Fassina G. Improvement of sensitivity for liver cancer detection by simultaneous evaluation of SCCA-IgM, AFP-IgM complexes and free AFP. J Hepatol. 44:S97. 2006. doi: 10.1016/S0168-8278(06)80242-4
30. Beneduce L, Prayer-Galetti T, Marcello Grimani Giustinian A, Gallotta A, Fracalanza S, Betto G, Artibani W, Pagano F. The occurrence of Prostate Specific Antigen-IgM immune complexes (IC) as novel serum biomarker for prostate cancer. Eur Urol Suppl. 5:163. 2006. doi: 10.1016/S1569-9056(06)60568-X
29. Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, Boscato N, Fassina G, Cavalletto L, Gatta A, Chemello L. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer. 119:735-40. 2006. doi: 10.1002/ijc.21908
28. Quarta S, Caberlotto C, Beneduce L, Marino M, Fassina G, Tono N, Cavalletto L, Chemello L, Gatta A, Pontisso P. Monitoring SCCA-IgM complex predicts HCC development in cirrhotic patients. J Hepatol. 44:S107. 2006.
27. Quarta S, Vidalino L, Ruvoletto M, Barbera MD, Calabrese F, Valente M, Beneduce L, Gatta A, Fassina G, Pontisso P. SCCA over-expression induces cell proliferation and down-regulation of the adhesion system. J Clin Virol. 36:S193. 2006.
26. Vidalino L, Quarta S, Baesso I, Cavasin L, Bernardinello E, Ruvoletto M, Frezzato F, Trentin L, Fassina G, Cavalletto L, Chemello L, Gatta A, Pontisso P. Deregulation of squamous cell carcinoma antigen (SCCA) expression in B lymphocytes in patients with chronic hepatitis C. J Clin Virol. 36:S28. 2006.
25. Vidalino L, Quarta S, Baesso I, Cavasin L, Bernardinello E, Trentin L, Fassina G, Cavalletto L, Chemello L, Gatta A, Pontisso P. SCCA expression in PBMCs in patients with chronic hepatitis C. Dig Liver Dis. 38:854-9. 2006.
24. Beneduce L, Castaldi F, Marino M, Pontisso P, Fassina G. Comparison of free and IgM-complexed squamous cell carcinoma antigen in hepatocellular carcinoma. J Hepatol. 42:89. 2005.
23. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegnù L, Calabrese F, Gatta A, Pontisso P, Fassina G. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer. 103:2558-65. 2005. doi: 10.1002/cncr.21106
22. Castaldi F, Marino M, Beneduce L, Belluco C, De Marchi F, Mammano E, Nitti D, Lise M, Fassina G. Detection of circulating CEA-IgM complexes in early stage colorectal cancer. Int J Biol Markers. 20(4):204-8. 2005.
21. Fassina G, Miertus S. Combinatorial chemistry and technologies: principles methods and applications. Combinatorial chemistry and technologies (second edition), Giorgio Fassina and Stanislav Miertus Editors. CRC Press, Boca Raton, FL pp 1-5. 2005.
20. Marino M, Beneduce L, Palomba D, Fiordelisi A, Fassina G. Combinatorial proteomic. Combinatorial chemistry and technologies (second edition), Giorgio Fassina and Stanislav Miertus Editors. CRC Press, Boca Raton, FL pp 523-38. 2005.
19. Nieddu E, Melchiori A, Pescarolo MP, Bagnasco L, Biasotti B, Licheri B, Malacarne D, Tortolina L, Castagnino N, Pasa S, Cimoli G, Avignolo C, Ponassi R, Balbi C, Patrone E, D\'Arrigo C, Barboro P, Vasile F, Orecchia P, Carnemolla B, Damonte G, Millo E, Palomba D, Fassina G, Mazzei M, Parodi S. Sequence specific peptidomimetic molecules inhibitors of a protein-protein interaction at the helix 1 level of c-Myc. FASEB J. 19:632-4. 2005.
18. Palomba D, Fassina G. Glycopeptides libraries in combinatorial chemistry and technologies: principles methods and applications. Combinatorial chemistry and technologies (second edition), Giorgio Fassina and Stanislav Miertus Editors. CRC Press, Boca Raton, FL pp 33-54. 2005.
17. Quarta S, Caberlotto C, Beneduce L, Castaldi F, Marino M, Fassina G, Tono N, Cavalletto L, Chemello L, Gatta A, Pontisso P. Serum SCCA-IgM complexes increase over time and HCC development in cirrhotic patients. Dig Liver Dis. 37:A38-A39. 2005.
16. Quarta S, Vidalino L, Ruvoletto M, Della Barbera M, Calabrese F, Valente M, Marino M, Beneduce L, Gatta A, Fassina G, Pontisso P. HCC invasiveness induced by SCCA is associated with nuclear beta-catenin accumulation. J Hepatol. 42:132. 2005.
15. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Pontisso P, Fassina G. Circulating squamous cell carcinoma antigen-IgM complexes as novel biomarkers for hepatocellular carcinoma. Dig Liver Dis. 36:A2-A3. 2004.
14. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Pontisso P, Fassina G. Serological detection of squamous cell carcinoma antigen-IgM complexes in hepatocellular carcinoma. J Hepatol. 40:77. 2004. doi: 10.1016/S0168-8278(04)90244-9
13. Beneduce L, Castaldi F, Marino M, Tono N, Gatta A, Pontisso P, Fassina G. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers. 19:155-9. 2004.
12. Marino M, Fassina G. Novel molecular targets for systemic lupus erythematosus and other immune-complex and T-cell mediated autoimmune disease. Med Res Rev. 1:331-2. 2004.
11. Pontisso P, Calabrese F, Benvegnù L, Belluco C, Ruvoletto M, Marino M, Beneduce L, Valente M, Nitti D, Alberti A, Gatta A, Fassina G. Squamous cell carcinoma antigen variants overexpression in hepatocellular carcinoma. Proceedings 11th International Symposium on Viral Hepatitis & Liver Disease. 445-6. 2004.
10. Pontisso P, Calabrese F, Benvegnù L, Lise M, Belluco C, Ruvoletto MG, Marino M, Valente M, Nitti D, Gatta A, Fassina G. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br J Cancer. 90:833-7. 2004. doi: 10.1038/sj.bjc.6601543
9. Pontisso P, Fassina G, Quarta S, Ruvoletto M, Tono N, Castaldi F, Nigro A, Marino M, Beneduce L, Gatta A. Nanotecnologie nella diagnostica dell'epatocarcinoma. Atti del 14° Conv. Int. Attualità e Prospettive in Epatologia. 144-8. 2004.
8. Ruvoletto MG, Tono N, Carollo D, Vilei T, Trentin L, Muraca M, Marino M, Gatta A, Fassina G, Pontisso P. Surface expression of squamous cell carcinoma antigen (SCCA) can be increased by the preS1 (21-47) sequence of hepatitis B virus. J Gen Virol. 85:621-4. 2004. doi: 10.1099/vir.0.19130-0
7. Van Rossum AP, Rarok AA, Huitema MG, Fassina G, Limburg PC, Kallenberg CGM. Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti-PR3 antibodies. J Leukoc Biol. 76:1162-70. 2004.
6. Fassina G, Miertus S. Combinatorial technologies in biotechnology. Chemistry Today. 3:28-31. 2003.
5. Palomba D, Fassina G. Combinatorial chemistry in biotechnology: novel ligands for affinity chromatography. Chemistry Today. 5:38-41. 2003.
4. Tanaka S, Edberg J, Chatham W, Fassina G, Kimberly R. Fc{gamma}RIIIb Allele-Sensitive Release of {alpha}-Defensins: Anti-Neutrophil Cytoplasmic Antibody-Induced Release of Chemotaxins. J Immunol. 171:6090-96. 2003.
3. Calabrese F, Belluco C, Benvegnù L, Ruvoletto M, Valente M, Marino M, Nitti D, Alberti A, Gatta A, Fassina G, Pontisso P. High expression of serine protease inhibitor (SCCA) variants in hepatocarcinoma. Dig Liver Dis. 34:155. 2002. doi: 10.1016/S1590-8658(02)80250-X
2. Ruvoletto M, Marino M, Tono N, Gatta A, Fassina G, Pontisso P. Surface expression of squamous cell carcinoma antigen (SCCA) variants can be upregulated by the pre s1 (21-47) sequence of HBV. J Hepatol. 36:83. 2002. doi: 10.1016/S0168-8278(02)80285-9
1. Fassina G. Combinatorial technologies in affinity chromatography: discovery of a novel synthetic ligand for antibody purification. Am Biotechnol Lab. 19:46-8. 2001.